본 『소아청소년 정신질환 연구를 위한 방법론 개발』은 소아 청소년의 주의력결핍과잉장애, 자폐증 그리고 청소년 우울증/자살의 발병 원인 규명, 진단, 예방, 치료 기술 개발을 위한 사전 조사 및 전략 도출에 관한 것으로, 관련 기술의 동향과 우리나라 기술수준에 대한 국내외 특허 분석을 통하여 상기 3대 정신 질환에 대한 향후 연구를 효율적으로 수행할 수 있는 구체적인 목표 및 방법을 도출이 가능하도록 보건복지가족부의 요청에 의해 특허청이 발주하고 R&D특허센터가 주관하는 사업임
분석 목적
본 특허동향조사 보고서는 소아 청소년의 주의력결핍과잉장애, 자폐증 그리고 청소년 우울증/자살을 포함하는 3대 정신질환을 연구하는데 있어서, 경쟁력 있는 진단, 예방 및 치료기술을 개발하기 위한 방법론을 도출하기 위하여 관련 분야의 특허동향 및 이를 바탕으로한 심층분석을 수행하고, 우리나라의 기술 수준, 선진기업의 연구개발 동향 및 핵심특허 현황 등을 파악하여본 연구개발과제와 관련된 객관적인 특허정보를 제공하기 위한 것임
본 보고서는 국가연구개발 기획단계에서 특허정보를 분석하여 우리나라 핵산 치료제 기술의 기술개발 추이 및 수준을 객관적으로 파악하고 효율적인 국가연구개발 정책수립을 위한 기초자료를 제공하고자,특허청의 용역사업으로 수행하여 발간한 특허동향조사?분석 결과입니다.
[소아청소년 정신질환 연구사업 특허동향中]
자료 출처: e- 특허나라
[더자세한내용을원하는분들을위해원본파일을첨부했습니다]
목차
주요분석결과 Ⅰ. 개 요 ···················································································· 1 제 1 절 분석 배경 및 목적 ······························································· 3 제 2 절 분석범위 ················································································· 4 제 3 절 분석기준 ················································································· 5 1. 기술 분류 ······················································································· 5 2. 분석 방법 ······················································································· 6 3. 분석 지표 ······················································································· 7 Ⅱ. 동향 분석 ·········································································· 11 제 1 절 특허동향 ················································································· 13 1. 국가별 특허동향 ········································································· 13 2. 출원인 국적별 특허동향 ··························································· 19 3. 국가별 주요 출원인 ··································································· 24 제 2 절 기술수준 ················································································· 26 1. 국가별 기술수준 현황 ······························································· 26 2. 세부기술별 특허동향 ································································· 29 3. 상위 다출원인별 중점분야 ······················································· 38 4. 기술 경쟁력 분석 ······································································· 41 5. 논문 분석 ····················································································· 44 제 3 절 동향분석 결론 ······································································· 46 Ⅲ. 심층분석 ············································································ 49 제 1 절 특허장벽 분석 ····································································· 51 1. 유전자를 이용한 진단방법 ······················································· 51 2. 비유전자 마커를 이용한 진단방법 ········································· 58 3. 비생물학적 수단을 이용한 진단방법 ····································· 62 제 2 절 요지 분석 ············································································· 65 1. 유전자를 이용한 진단방법 ······················································· 66 2. 비유전자 마커를 이용한 진단방법 ········································· 97 3. 비생물학적 수단을 이용한 진단방법 ··································· 104 제 3 절 기술망 분석 ······································································· 111 1. 유전자 마커관련 기술망 ························································· 115 2. 특허화 전략 ··············································································· 122 3. R&D 전략 ·················································································· 123 제 4 절 주요 출원인 분석 ····························································· 127 1. F. Hoffmann-La Roche ··························································· 127 2. Wyeth ························································································· 134 Ⅳ. 결론 ·················································································· 139 제 1 절 결론 및 시사점 ································································· 141 1. 동향분석 결론 ··········································································· 141 2. 심층분석 결론 ··········································································· 144 Ⅴ. 첨 부 ················································································ 147